Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: HRT012
MIFTS: 57

Heart Valve Disease

Categories: Blood diseases, Cardiovascular diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Heart Valve Disease

About this section

MalaCards integrated aliases for Heart Valve Disease:

Name: Heart Valve Disease 39 12 15 17 74 64
Abnormality of the Heart Valves 30 6
Valvular Heart Disease 12 15
Heart Valve Diseases 44 45
Valvular Heart Diseases 56
Heart Valve Prolapse 45

Classifications:

MalaCards categories:
Anatomical: Cardiovascular diseases Blood diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:4079
NCIt 51 C45525
SNOMED-CT 69 368009
Sources

Summaries for Heart Valve Disease

About this section
MedlinePlus : 44 Your heart has four valves. Normally, these valves open to let blood flow through or out of your heart, and then shut to keep it from flowing backward. But sometimes they don't work properly. If they don't, you could have Regurgitation - when blood leaks back through the valve in the wrong direction Mitral valve prolapse - when one of the valves, the mitral valve, has "floppy" flaps and doesn't close tightly. It's one of the most common heart valve conditions. Sometimes it causes regurgitation. Stenosis - when the valve doesn't open enough and blocks blood flow Valve problems can be present at birth or caused by infections, heart attacks, or heart disease or damage. The main sign of heart valve disease is an unusual heartbeat sound called a heart murmur. Your doctor can hear a heart murmur with a stethoscope. But many people have heart murmurs without having a problem. Heart tests can show if you have a heart valve disease. Some valve problems are minor and do not need treatment. Others might require medicine, medical procedures, or surgery to repair or replace the valve. NIH: National Heart, Lung, and Blood Institute

MalaCards based summary : Heart Valve Disease, also known as abnormality of the heart valves, is related to orthostatic intolerance and rheumatic heart disease, and has symptoms including angina pectoris, edema and chest pain. An important gene associated with Heart Valve Disease is SMC1A (Structural Maintenance Of Chromosomes 1A), and among its related pathways/superpathways are Development Endothelin-1/EDNRA signaling and G-protein signaling Regulation of p38 and JNK signaling mediated by G-proteins. The drugs Amiodarone and Warfarin have been mentioned in the context of this disorder. Affiliated tissues include Heart and Heart, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Disease Ontology : 12 A heart disease involving one or more of the four valves of the heart (the aortic and mitral valves on the left and the pulmonary and tricuspid valves on the right).

PubMed Health : 64 About heart valve disease: Heart valve disease occurs if one or more of your heart valves don't work well. The heart has four valves: the tricuspid (tri-CUSS-pid), pulmonary (PULL-mun-ary), mitral (MI-trul), and aortic (ay-OR-tik) valves.These valves have tissue flaps that open and close with each heartbeat. The flaps make sure blood flows in the right direction through your heart's four chambers and to the rest of your body.

Wikipedia : 77 Valvular heart disease is any cardiovascular disease process involving one or more of the four valves of... more...

Sources

Related Diseases for Heart Valve Disease

About this section

Diseases related to Heart Valve Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 192)
# Related Disease Score Top Affiliating Genes
1 orthostatic intolerance 32.3 ELN FBN1 PDLIM1
2 rheumatic heart disease 31.9 ACE MYOM2 TGFB1
3 dilated cardiomyopathy 31.3 ACE CRP CTF1 IL1B NPPA NPPB
4 heart disease 31.2 ACE CRP ELN IL1B NPPA NPPB
5 atrial fibrillation 30.8 ACE CRP NPPA NPPB VWF
6 congestive heart failure 30.6 ACE NPPA NPPB NR3C2
7 pericarditis 30.5 CRP IL1B NPPB
8 mitral valve disease 30.4 ACE FBN1 NPPA
9 coronary stenosis 30.3 ACE CRP NPPB VWF
10 vasculitis 30.2 APOH CRP VWF
11 coronary artery anomaly 30.2 ACE CRP NPPA NPPB
12 arteries, anomalies of 30.2 ACE CRP IL1B NPPB VWF
13 sleep apnea 30.2 ACE CRP HTR2A IL1B NPPB
14 aortic disease 30.1 CRP ELN FBN1
15 mitral valve stenosis 30.1 HCK NPPA NPPB
16 pulmonary hypertension 30.0 ACE HTR2B NPPA NPPB VWF
17 systemic scleroderma 30.0 ACE CRP FBN1 TGFB1
18 pulmonary embolism 30.0 APOH CRP NPPB VWF
19 systemic lupus erythematosus 30.0 ACE APOH CRP IL1B TGFB1 VWF
20 aortic valve insufficiency 29.9 ACE ELN FBN1 NPPB
21 pulmonary edema 29.9 ACE CRP IL1B NPPA NPPB
22 chronic kidney failure 29.9 ACE CRP NPPA NPPB TGFB1
23 mitral valve insufficiency 29.8 ACE FBN1 HCK NPPA NPPB PDLIM1
24 kidney disease 29.7 ACE CRP NPPA NPPB NR3C2 TGFB1
25 myocardial infarction 29.2 ACE CRP CTF1 IL1B NPPA NPPB
26 aortic valve disease 1 28.7 ACE CRP ELN FBN1 HCK NPPB
27 aortic valve disease 2 28.5 ACE CNMD CRP ELN HCK NPPA
28 short stature valvular heart disease 12.3
29 cardiac valvular defect, developmental 11.7
30 cardiac valvular dysplasia, x-linked 11.6
31 tricuspid valve stenosis 11.4
32 disproportionate short stature with ptosis and valvular heart lesions 11.3
33 andersen cardiodysrhythmic periodic paralysis 11.1
34 cardiomyopathy, familial hypertrophic, 21 11.1
35 cardiovascular system disease 11.1
36 coumarin resistance 11.0
37 tricuspid valve disease 11.0
38 sick sinus syndrome 11.0
39 esterase c 10.5
40 pseudoxanthoma elasticum-like papillary dermal elastolysis 10.4 ELN FBN1
41 late-onset focal dermal elastosis 10.4 ELN FBN1
42 familial vesicoureteral reflux 10.4 ACE TGFB1
43 hepatoportal sclerosis 10.4 ACE ELN
44 familial abdominal aortic aneurysm 10.4 ELN FBN1
45 autoimmune atherosclerosis 10.4 ACE APOH
46 chronic fatigue syndrome 10.4 HTR2A IL1B TGFB1
47 bone fracture 10.4 CRP TGFB1
48 plica syndrome 10.4 ELN VWF
49 silicosis 10.4 ACE IL1B TGFB1
50 anterolateral myocardial infarction 10.4 ACE NPPA NPPB

Graphical network of the top 20 diseases related to Heart Valve Disease:



Diseases related to Heart Valve Disease
Sources

Symptoms & Phenotypes for Heart Valve Disease

About this section

UMLS symptoms related to Heart Valve Disease:


angina pectoris, edema, chest pain, undiagnosed heart murmur

GenomeRNAi Phenotypes related to Heart Valve Disease according to GeneCards Suite gene sharing:

27 (show all 34)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-100 9.92 IL1B
2 Increased shRNA abundance (Z-score > 2) GR00366-A-102 9.92 IL1B
3 Increased shRNA abundance (Z-score > 2) GR00366-A-105 9.92 TGFB1
4 Increased shRNA abundance (Z-score > 2) GR00366-A-115 9.92 IL1R1
5 Increased shRNA abundance (Z-score > 2) GR00366-A-116 9.92 IL1B IL1R1 TGFB1
6 Increased shRNA abundance (Z-score > 2) GR00366-A-120 9.92 TGFB1
7 Increased shRNA abundance (Z-score > 2) GR00366-A-122 9.92 IL1R1
8 Increased shRNA abundance (Z-score > 2) GR00366-A-123 9.92 NR3C2
9 Increased shRNA abundance (Z-score > 2) GR00366-A-124 9.92 IL1R1
10 Increased shRNA abundance (Z-score > 2) GR00366-A-140 9.92 TGFB1
11 Increased shRNA abundance (Z-score > 2) GR00366-A-143 9.92 TGFB1
12 Increased shRNA abundance (Z-score > 2) GR00366-A-168 9.92 IL1B IL1R1
13 Increased shRNA abundance (Z-score > 2) GR00366-A-169 9.92 TGFB1
14 Increased shRNA abundance (Z-score > 2) GR00366-A-170 9.92 IL1B
15 Increased shRNA abundance (Z-score > 2) GR00366-A-176 9.92 NR3C2
16 Increased shRNA abundance (Z-score > 2) GR00366-A-178 9.92 TGFB1
17 Increased shRNA abundance (Z-score > 2) GR00366-A-183 9.92 IL1R1
18 Increased shRNA abundance (Z-score > 2) GR00366-A-185 9.92 NR3C2
19 Increased shRNA abundance (Z-score > 2) GR00366-A-198 9.92 IL1B IL1R1 NR3C2 TGFB1
20 Increased shRNA abundance (Z-score > 2) GR00366-A-199 9.92 IL1B
21 Increased shRNA abundance (Z-score > 2) GR00366-A-207 9.92 NR3C2
22 Increased shRNA abundance (Z-score > 2) GR00366-A-208 9.92 NR3C2
23 Increased shRNA abundance (Z-score > 2) GR00366-A-25 9.92 IL1R1
24 Increased shRNA abundance (Z-score > 2) GR00366-A-35 9.92 TGFB1
25 Increased shRNA abundance (Z-score > 2) GR00366-A-50 9.92 IL1B
26 Increased shRNA abundance (Z-score > 2) GR00366-A-51 9.92 IL1B
27 Increased shRNA abundance (Z-score > 2) GR00366-A-56 9.92 TGFB1
28 Increased shRNA abundance (Z-score > 2) GR00366-A-70 9.92 NR3C2
29 Increased shRNA abundance (Z-score > 2) GR00366-A-77 9.92 TGFB1
30 Increased shRNA abundance (Z-score > 2) GR00366-A-79 9.92 IL1B
31 Increased shRNA abundance (Z-score > 2) GR00366-A-81 9.92 IL1B
32 Increased shRNA abundance (Z-score > 2) GR00366-A-9 9.92 IL1R1
33 Increased shRNA abundance (Z-score > 2) GR00366-A-97 9.92 NR3C2
34 Increased shRNA abundance (Z-score > 2) GR00366-A-99 9.92 IL1R1

MGI Mouse Phenotypes related to Heart Valve Disease:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.9 ACE CRP FBN1 HCK HTR2B IL1B
2 adipose tissue MP:0005375 9.73 ACE CTF1 FBN1 HTR2B IL1R1 TGFB1
3 hematopoietic system MP:0005397 9.73 ACE CNMD FBN1 HCK IL1B IL1R1
4 homeostasis/metabolism MP:0005376 9.47 ACE APOH CNMD CRP CTF1 FBN1
Sources

Drugs & Therapeutics for Heart Valve Disease

About this section

PubMedHealth treatment related to Heart Valve Disease: 64

Currently, no medicines can cure heart valve disease. However, lifestyle changes and medicines often can successfully treat symptoms and delay problems for many years. Eventually, though, you may need surgery to repair or replace a faulty heart valve.The goals of treating heart valve disease might include:Preventing, treating, or relieving the symptoms of other related heart conditions.Protecting heart valves from further damage.Repairing or replacing faulty valves when they cause severe symptoms or become life threatening. Replacement valves can be man-made or biological.

Drugs for Heart Valve Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 427)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Amiodarone Approved, Investigational Phase 4,Phase 3,Not Applicable 1951-25-3 2157
2
Warfarin Approved Phase 4,Phase 2,Phase 3,Not Applicable 81-81-2 6691 54678486
3
Atorvastatin Approved Phase 4,Phase 3 134523-00-5 60823
4
Desflurane Approved Phase 4,Not Applicable 57041-67-5 42113
5
Propofol Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 2078-54-8 4943
6
Ranolazine Approved, Investigational Phase 4 142387-99-3, 95635-55-5 56959
7
Tadalafil Approved, Investigational Phase 4 171596-29-5 110635
8
Trandolapril Approved Phase 4 87679-37-6 5484727
9
Captopril Approved Phase 4 62571-86-2 44093
10
Spironolactone Approved Phase 4,Not Applicable 52-01-7, 1952-01-7 5833
11
Sufentanil Approved, Investigational Phase 4,Phase 2,Not Applicable 56030-54-7 41693
12
Ketamine Approved, Vet_approved Phase 4,Phase 2,Not Applicable 6740-88-1 3821
13
Remifentanil Approved Phase 4,Phase 2,Not Applicable 132875-61-7 60815
14
Midazolam Approved, Illicit Phase 4,Phase 2,Not Applicable 59467-70-8 4192
15
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 2 437-38-7 3345
16
Dopamine Approved Phase 4,Phase 3,Phase 2,Not Applicable 62-31-7, 51-61-6 681
17
Candesartan cilexetil Approved Phase 4,Phase 3,Phase 2 145040-37-5 2540
18
Angiotensin II Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 68521-88-0, 11128-99-7, 4474-91-3 172198 65143
19
Aspirin Approved, Vet_approved Phase 4,Phase 3,Not Applicable 50-78-2 2244
20
Clopidogrel Approved Phase 4,Phase 3,Not Applicable,Early Phase 1 120202-66-6, 113665-84-2 60606
21
Ticagrelor Approved Phase 4,Phase 3,Early Phase 1 274693-27-5 9871419
22
Rivaroxaban Approved Phase 4,Phase 3,Phase 2 366789-02-8
23
Phylloquinone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 84-80-0
24
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
25
Metoprolol Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 37350-58-6, 51384-51-1 4171
26
Dexmedetomidine Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 113775-47-6 68602 5311068
27
Sodium Citrate Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable,Early Phase 1 68-04-2
28
Sevoflurane Approved, Vet_approved Phase 4,Phase 2,Early Phase 1 28523-86-6 5206
29
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
30
Thiopental Approved, Vet_approved Phase 4 76-75-5 3000715
31
Etomidate Approved Phase 4,Phase 2 33125-97-2 36339 667484
32
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754
33
Isoflurane Approved, Vet_approved Phase 4,Not Applicable 26675-46-7 3763
34
Epinephrine Approved, Vet_approved Phase 4,Not Applicable 51-43-4 5816
35
Dobutamine Approved Phase 4,Not Applicable 34368-04-2 36811
36
Racepinephrine Approved Phase 4,Not Applicable 329-65-7 838
37
Norepinephrine Approved Phase 4 51-41-2 439260
38
Valsartan Approved, Investigational Phase 4,Phase 2,Phase 3 137862-53-4 60846
39
Tolvaptan Approved Phase 4 150683-30-0 216237
40
Neostigmine Approved, Vet_approved Phase 4 59-99-4 4456
41
Aminocaproic Acid Approved, Investigational Phase 4 60-32-2 564
42 Nutmeg Approved Phase 4,Not Applicable
43
Cosyntropin Approved Phase 4 16960-16-0 16129617
44
Acetazolamide Approved, Vet_approved Phase 4 59-66-5 1986
45
Heparin Approved, Investigational Phase 4,Phase 3,Not Applicable,Early Phase 1 9005-49-6 772 46507594
46
Losartan Approved Phase 4,Phase 2,Not Applicable 114798-26-4 3961
47
Acetylcysteine Approved, Investigational Phase 4,Phase 2,Phase 1 616-91-1 12035
48
Acenocoumarol Approved, Investigational Phase 4 152-72-7 9052 54676537
49
Regadenoson Approved, Investigational Phase 4,Phase 1,Phase 2,Not Applicable 313348-27-5 219024
50
Adenosine Approved, Investigational Phase 4,Phase 1,Phase 2 58-61-7 60961

Interventional clinical trials:

(show top 50) (show all 1390)
# Name Status NCT ID Phase Drugs
1 The Pharmacogenetics of Optimal Warfarin Therapy in Chinese Patients After Heart Valve Replacement. Unknown status NCT02710747 Phase 4
2 Frailty and Cognitive Function Assessment of TAVI Patients Unknown status NCT02650388 Phase 4
3 The ABC Trial Does All-Blood Cardioplegia Prevent Blood Transfusion in Cardiac Surgery? A Single Centre Pilot Study Unknown status NCT01623193 Phase 4
4 Applying Pharmacogenetics to Warfarin Dosing in Chinese Patients Unknown status NCT01610141 Phase 4
5 Effects of Atorvastatin Treatment on Left Ventricular Diastolic Function in Peritoneal Dialysis Patients Unknown status NCT01503671 Phase 4 Atorvastatin
6 (MitraClip in Non-Responders to Cardiac Resynchronization Therapy) Unknown status NCT02592889 Phase 4
7 Abrogation of Mitral Regurgitation Using the MitraClip System in High-Risk Patients Unsuitable for Surgery Unknown status NCT01431222 Phase 4
8 Surgical Treatment of Ischemic Mitral Regurgitation Unknown status NCT01368575 Phase 4
9 The Pacing vs No Pacing Study - PNP Study Unknown status NCT02498639 Phase 4
10 Desflurane-induced Myocardial Protection Unknown status NCT02019797 Phase 4 Desflurane
11 Effect of Ranolazine on Valvular Disease in Patients With Pacemakers Unknown status NCT01979965 Phase 4 Ranolazine (Active drug);Placebo
12 A Randomized Trial of Angiotensin Receptor bLocker,Fimasartan, in Aortic Stenosis (ALFA Trial) Unknown status NCT01589380 Phase 4 Fimasartan;Placebo
13 Aortic Stenosis and PhosphodiEsterase Type 5 iNhibition (ASPEN): A Pilot Study Unknown status NCT01275339 Phase 4 Tadalafil;Placebo
14 Physiological Response to Heliox21 and Air O2 Unknown status NCT01498432 Phase 4 Heliox21;Air O2
15 Acute Haemodynamic Effects of Treatment With Angiotensin Converting Enzyme (ACE)-Inhibitors in Patients With Symptomatic Aortic Stenosis Unknown status NCT00252317 Phase 4 Captopril and Trandolapril;Captopril Test Dose and Trandolapril
16 Pilot Study of Lovaza (Omega 3 Fatty Acids) to Improve Cardiac Antioxidant/Anti-inflammatory Profile Before Cardiac Surgery Unknown status NCT01046604 Phase 4 Lovaza group
17 Endothelial Progenitors in Aortic Stenosis: Association With Aortic Stenosis Progression and Severity Unknown status NCT02060071 Phase 4
18 Comparative Study of Non-Invasive Mask Ventilation vs Cuirass Ventilation in Patients With Acute Respiratory Failure. Unknown status NCT00331656 Phase 4
19 Study of Administration Of Antithrombin in Patients With Low Plasmatic Levels of Antithrombin After Cardiac Surgery Unknown status NCT01201070 Phase 4 antithrombin III
20 Clinical and Therapeutic Implications of Fibrosis in Hypertrophic Cardiomyopathy Unknown status NCT00879060 Phase 4 spironolactone
21 Immunonutrition and Thoracoabdominal Aorta Aneurysm Repair Unknown status NCT00339053 Phase 4 Immunonutrition ( Impact)
22 Effect of Propofol on Renal Injury in Patients Undergoing Valvular Heart Surgery Completed NCT01384643 Phase 4 Propofol
23 The Effects of Levosimendan on Haemodynamics in Patients Undergoing Elective Aortic Valve Replacement (AVR)Together With Coronary Artery Bypass Grafting (CABG) Surgery Completed NCT01210976 Phase 4 levosimendan;placebo
24 Effect of Combined Remote Ischemic Preconditioning and Postconditioning on Acute Pulmonary Injury in Patients Undergoing Valvular Heart Surgery Completed NCT01427621 Phase 4
25 A Randomized Clinical Trial of Metoprolol in Participants With Mitral Regurgitation. Completed NCT00166400 Phase 4 metoprolol succinate
26 Comparative Effects of Dexmedetomidine and Ketofol for Sedation in Patients Undergoing Trans-esophageal Echocardiography Completed NCT02867930 Phase 4 Dexmedetomidine;Ketofol(ketamine+propofol)
27 Sildenafil for Secondary Pulmonary Hypertension Due to Valvular Disease Completed NCT00862043 Phase 4 Sildenafil Citrate;Placebo
28 Effect of Anesthetics on CD39 and CD73 After Open-heart Surgery Completed NCT02136979 Phase 4 Propofol;Sevoflurane
29 Propofol Effects on Mitral Valve Annular Velocity Completed NCT01826149 Phase 4 Propofol 1.0mcg;Propofol 2.0mcg;Propofol 3.0mcg
30 Humanalbumin, Hydroxyethylstarch and Ringer Lactate During Cardiac Surgery Completed NCT01174719 Phase 4 volume replacement;Humanalbumin 5%;volume replacement
31 The Cortisol Levels During Cardiac Surgery. The Comparison Between Etomidate and Thiopentone Completed NCT01495949 Phase 4 etomidate;thiopentone
32 Randomized Isoflurane and Sevoflurane Comparison in Cardiac Surgery Completed NCT01477151 Phase 4 Volatile anesthetic
33 Ontario Multidetector Computed Tomographic (MDCT) Coronary Angiography Study (OMCAS) Completed NCT00371891 Phase 4
34 The Use of Paravertebral Block for Cardiac Surgery Completed NCT02180893 Phase 4
35 The Effects of Levosimendan During Mitral Valve Surgery Completed NCT01969071 Phase 4 Levosimendan;Dobutamine
36 Beating Versus Arrested Heart for Mitral Valve Replacement Completed NCT01641614 Phase 4
37 CG Future® Annuloplasty Ring/Band Clinical Trial Completed NCT01074671 Phase 4
38 Angiotensin-II Blockade in Mitral Regurgitation Completed NCT00587470 Phase 4 Candesartan;atacand;Placebo
39 Pharmacological Reduction of Functional, Ischemic Mitral REgurgitation Completed NCT02687932 Phase 4 LCZ696;Valsartan
40 The Safety and Efficacy of Tolvaptan for Patients With Tricuspid Regurgitation and Right Heart Failure After Left Heart Valves Replacement Completed NCT02644616 Phase 4 tolvaptan+torasemide;placebo+torasemide
41 Tricuspid Regurgitation Study Completed NCT01093001 Phase 4
42 Cerebral Embolic Load in Patients Undergoing Surgical Aortic Valve Replacement: A Comparison of the Conventional With the Minimized Extracorporeal Circulation Technique Using Transcranial Doppler Ultrasound Completed NCT02308566 Phase 4
43 Platelet Reactivity After TAVI: A Multicenter Pilot Study Completed NCT02224066 Phase 4 Ticagrelor 90 mg twice per day during three months following TAVI;Aspirin 100 mg plus Clopidogrel 75 mg daily during three months following TAVI
44 Effect of Beta Blockade on Left Ventricular Remodeling and Function in Moderate to Severe Asymptomatic Aortic Regurgitation Completed NCT01157572 Phase 4 Metoprolol;Placebo
45 REST Study: Left Ventricular Regression European Study Completed NCT00256165 Phase 4
46 Effect of Neuromuscular Blockade and Reversal on Breathing Completed NCT02845375 Phase 4 Sugammadex;Neostigmine;Placebo
47 Effect of Non-invasive Ventilation (NIV) on Cerebral Oxygenation Completed NCT02454582 Phase 4
48 Acute Hemodynamic Effects of Sildenafil in Patients With Severe Aortic Stenosis Completed NCT01060020 Phase 4 Sildenafil
49 Platelet Function And Aggregometry In Patients With Aortic Valve Stenosis Completed NCT00156520 Phase 4 aprotonin; epsilon aminocaproic acid
50 Effects of Remifentanil on Respiratory Function in Mechanically Ventilated Patients Completed NCT00665119 Phase 4 remifentanil;placebo

Search NIH Clinical Center for Heart Valve Disease

Cochrane evidence based reviews: heart valve diseases

Sources

Genetic Tests for Heart Valve Disease

About this section

Genetic tests related to Heart Valve Disease:

# Genetic test Affiliating Genes
1 Abnormality of the Heart Valves 30
Sources

Anatomical Context for Heart Valve Disease

About this section

MalaCards organs/tissues related to Heart Valve Disease:

42
Heart, Lung, Testes, Kidney, Brain, Endothelial, Liver
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Heart Valve Disease:
# Tissue Anatomical CompartmentCell Relevance
1 Heart Atrioventricular Valves Atrioventricular Valve Cells Affected by disease
2 Heart Semilunar Valves Semilunar Valve Cells Affected by disease
Sources

Publications for Heart Valve Disease

About this section

Articles related to Heart Valve Disease:

(show top 50) (show all 128)
# Title Authors Year
1
3D printing for heart valve disease: a systematic review. ( 30771098 )
2019
2
Heart valve disease in elderly. ( 30820277 )
2019
3
von Willebrand Factor and Management of Heart Valve Disease: JACC Review Topic of the Week. ( 30846101 )
2019
4
Bacterial infiltration in structural heart valve disease. ( 30885626 )
2019
5
Periodontal bacteria DNA findings in human cardiac tissue - Is there a link of periodontitis to heart valve disease? ( 29197463 )
2018
6
Antiphospholipid Antibodies and Heart Valve Disease in Systemic Lupus Erythematosus. ( 29549933 )
2018
7
Engineering a 3D-Bioprinted Model of Human Heart Valve Disease Using Nanoindentation-Based Biomechanics. ( 29751516 )
2018
8
Comorbid TNF-mediated heart valve disease and chronic polyarthritis share common mesenchymal cell-mediated aetiopathogenesis. ( 29475857 )
2018
9
The Right Heart-Pulmonary Circulation Unit and Left Heart Valve Disease. ( 29966640 )
2018
10
What's hot in heart valve disease 2018? ( 29334507 )
2018
11
Comprehensive microRNA profiling reveals potential augmentation of the IL1 pathway in rheumatic heart valve disease. ( 29548280 )
2018
12
Patient-Specific MRI-Based CFD for Optimizing Surgical Decision Making in Heart Valve Disease. ( 29667252 )
2018
13
Heart Valve Disease Awareness Survey 2017: what did we achieve since 2015? ( 29943272 )
2018
14
Murmur clinic: validation of a new model for detecting heart valve disease. ( 30049836 )
2018
15
Correction to: Heart Valve Disease Awareness Survey 2017: what did we achieve since 2015? ( 30155733 )
2018
16
Heart Valve Disease Predict Mortality in Hemodiaylsis Patients: A Single Center Experience. ( 30421548 )
2018
17
Clinical information has low sensitivity for postmortem diagnosis of heart valve disease. ( 28183793 )
2017
18
Standardization of adult transthoracic echocardiography reporting in agreement with recent chamber quantification, diastolic function, and heart valve disease recommendations: an expert consensus document of the European Association of Cardiovascular Imaging. ( 29045589 )
2017
19
Autoantibodies to types I and IV collagen and heart valve disease in systemic lupus erythematosus/antiphospholipid syndrome. ( 28283766 )
2017
20
What's hot in heart valve disease 2017? ( 28067716 )
2017
21
Appropriateness criteria for the use of cardiovascular imaging in heart valve disease in adults: a European Association of Cardiovascular Imaging report of literature review and current practice. ( 28586420 )
2017
22
Evaluating Health of Emerging Economies Through the Eyes of Heart Valve Disease inA theA Transcatheter Era. ( 28433490 )
2017
23
DNA methylation dysregulations in rheumatic heart valve disease. ( 28623907 )
2017
24
Cardiovascular magnetic resonance in the evaluation of heart valve disease. ( 29284450 )
2017
25
Selection of the Best of 2016 in Echocardiography in Heart Valve Disease. ( 28254138 )
2017
26
Regulation of valve interstitial cell homeostasis by mechanical deformation: implications for heart valve disease and surgical repair. ( 29046338 )
2017
27
Pregnancy and native heart valve disease. ( 27390366 )
2016
28
Detecting heart valve disease: can we do better? ( 26917654 )
2016
29
OS 01-07 CLINICAL IMPORTANCE OF COLLAGEN METABOLISM MARKERS IN RHEUMATIC HEART VALVE DISEASE IN INDIAN SUBPOPULATION. ( 27753898 )
2016
30
Prof. David S. Bach: heart valve disease. ( 27054110 )
2016
31
Multimodality imaging in heart valve disease. ( 26977308 )
2016
32
Changing causes of heart valve disease mortality in New Zealand from 1988 to 2007. ( 26914193 )
2016
33
Heart valve disease: looking back and moving forward. ( 26841326 )
2016
34
Heart valve disease in elderly Chinese population: effect of advanced age and comorbidities on treatment decision-making and outcomes. ( 27605940 )
2016
35
Aortic valve stenosis: what do people know? A heart valve disease awareness survey of over 8,800 people aged 60 or over. ( 27283409 )
2016
36
OS 01-07 CLINICAL IMPORTANCE OF COLLAGEN METABOLISM MARKERS IN RHEUMATIC HEART VALVE DISEASE IN INDIAN SUBPOPULATION. ( 27643244 )
2016
37
Methylphenidate: pulmonary hypertension and heart valve disease. ( 26436168 )
2015
38
The modern epidemiology of heart valve disease. ( 26541169 )
2015
39
Carcinoid Heart Valve Disease: Transcatheter Pulmonary Valve-In-Valve Implantation in Failing Biological Xenografts. ( 26182628 )
2015
40
Tricuspid Annuloplasty for Tricuspid Regurgitation Secondary to Left-Sided Heart Valve Disease: Immediate Outcomes and Risk Factors for Late Failure. ( 26777269 )
2015
41
Failing stentless Bioprostheses in patients with carcinoid heart valve disease. ( 25880286 )
2015
42
Automatic extraction of forward stroke volume using dynamic PET/CT: a dual-tracer and dual-scanner validation in patients with heart valve disease. ( 26501826 )
2015
43
Heart valve disease in general practice: a clinical overview. ( 25733443 )
2015
44
Aortic regurgitation and heart valve disease in mice. ( 26623080 )
2015
45
Spontaneous retrotransposon insertion into TNF 3'UTR causes heart valve disease and chronic polyarthritis. ( 26195802 )
2015
46
Deregulation of TNF expression can also cause heart valve disease. ( 26321488 )
2015
47
How should specialist competencies in heart valve disease be recognized? ( 25609702 )
2015
48
'Black box warning' on food and drug administration criteria for drug-induced heart valve disease? ( 25535216 )
2015
49
Heart valve disease: The role of calcidiol deficiency, elevated parathyroid hormone levels and oxidative stress in mitral and aortic valve insufficiency. ( 24192717 )
2014
50
Benfluorex: left heart valve disease very common. ( 24926516 )
2014
Sources

Variations for Heart Valve Disease

About this section

ClinVar genetic disease variations for Heart Valve Disease:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 SMC1A NM_006306.3(SMC1A): c.802_804delAAG (p.Lys268del) deletion Pathogenic rs727503773 GRCh37 Chromosome X, 53439900: 53439902
2 SMC1A NM_006306.3(SMC1A): c.802_804delAAG (p.Lys268del) deletion Pathogenic rs727503773 GRCh38 Chromosome X, 53412950: 53412952
Sources

Expression for Heart Valve Disease

About this section
Search GEO for disease gene expression data for Heart Valve Disease.
Sources

Pathways for Heart Valve Disease

About this section

Pathways related to Heart Valve Disease according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Development Endothelin-1/EDNRA signaling 23
Show member pathways
 11.94 HTR2A HTR2B IL1B IL1R1 NPPB
2
G-protein signaling Regulation of p38 and JNK signaling mediated by G-proteins 23
Show member pathways
 11.91 ELN FBN1 HCK IL1B IL1R1
3
Amoebiasis 38
11.53 IL1B IL1R1 TGFB1
4
Agents Acting on the Renin-Angiotensin System Pathway, Pharmacodynamics 62
Show member pathways
 11.4 ACE NR3C2 TGFB1
5
Elastic fibre formation 67
Show member pathways
 11.3 ELN FBN1 TGFB1
6
Lung fibrosis 1
11.13 ELN IL1B TGFB1
7
MicroRNAs in cardiomyocyte hypertrophy 1
Show member pathways
 11.13 CTF1 NPPA NPPB TGFB1
Sources

GO Terms for Heart Valve Disease

About this section

Cellular components related to Heart Valve Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.81 ACE APOH CRP CTF1 FBN1 IL1B
2 extracellular region GO:0005576 9.44 ACE APOH CNMD CRP CTF1 ELN
3 extracellular matrix GO:0031012 9.43 ELN FBN1 TGFB1
4 collagen-containing extracellular matrix GO:0062023 9.43 APOH ELN FBN1 NPPA TGFB1 VWF

Biological processes related to Heart Valve Disease according to GeneCards Suite gene sharing:

(show all 23)
# Name GO ID Score Top Affiliating Genes
1 inflammatory response GO:0006954 9.85 CRP HCK IL1B IL1R1 TGFB1
2 positive regulation of cell proliferation GO:0008284 9.8 CTF1 HCK HTR2A HTR2B IL1B TGFB1
3 cellular calcium ion homeostasis GO:0006874 9.77 HTR2A HTR2B TGFB1
4 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.76 HTR2A HTR2B TGFB1
5 cellular response to mechanical stimulus GO:0071260 9.73 IL1B NPPA TGFB1
6 regulation of blood pressure GO:0008217 9.69 ACE NPPA NPPB
7 positive regulation of MAP kinase activity GO:0043406 9.67 HTR2A HTR2B TGFB1
8 response to hypoxia GO:0001666 9.65 NPPA PDLIM1 TGFB1
9 blood coagulation, intrinsic pathway GO:0007597 9.61 APOH VWF
10 positive regulation of superoxide anion generation GO:0032930 9.61 CRP TGFB1
11 regulation of blood vessel diameter GO:0097746 9.59 ACE NPPB
12 cGMP biosynthetic process GO:0006182 9.58 NPPA NPPB
13 positive regulation of cell division GO:0051781 9.58 HTR2B IL1B TGFB1
14 receptor guanylyl cyclase signaling pathway GO:0007168 9.57 NPPA NPPB
15 behavior GO:0007610 9.55 HTR2A HTR2B
16 cytokine-mediated signaling pathway GO:0019221 9.55 CTF1 HCK IL1B IL1R1 TGFB1
17 cellular response to insulin-like growth factor stimulus GO:1990314 9.54 FBN1 TGFB1
18 serotonin receptor signaling pathway GO:0007210 9.52 HTR2A HTR2B
19 positive regulation of T-helper 1 cell cytokine production GO:2000556 9.43 IL1B IL1R1
20 lipopolysaccharide-mediated signaling pathway GO:0031663 9.43 HCK IL1B TGFB1
21 positive regulation of phosphatidylinositol biosynthetic process GO:0010513 9.37 HTR2A HTR2B
22 regulation of signaling receptor activity GO:0010469 9.1 CTF1 FBN1 IL1B NPPA NPPB TGFB1
23 mononuclear cell proliferation GO:0032943 8.96 ACE TGFB1

Molecular functions related to Heart Valve Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 hormone activity GO:0005179 9.5 FBN1 NPPA NPPB
2 drug binding GO:0008144 9.33 ACE HTR2A HTR2B
3 serotonin binding GO:0051378 9.26 HTR2A HTR2B
4 extracellular matrix constituent conferring elasticity GO:0030023 8.96 ELN FBN1
5 hormone receptor binding GO:0051427 8.62 NPPA NPPB
Sources

Sources for Heart Valve Disease

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....